Beta Drugs Ltd
Ticker: BETA
Decent
48/100
☆ Add to Watchlist
Investing Reference
Price
1711.40
Market Cap
1727.58
Debt/Equity
0.7004
ROE %
23.953
PB
8.7654
Promoter %
66.734
Pledge %
0.000
1Y Rev Growth %
24.146
5Y Rev Growth %
32.233
NP Margin %
11.502
NP Margin 5Y Avg %
12.149
Trading Reference
1M Return %
-6.071
6M Return %
-7.342
1Y Return %
-6.515
% Away 52W High
29.440
% Away 52W Low
19.718
Daily Volume
1575
Investment Verdict
Hold
Score 64/100 · Position size: 30%
Fundamentals are OK but not compelling. Maintain current position; avoid fresh adds.
Trading Verdict
Avoid
Score 24/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
AI Probability Statement
Probability Statement
Beta Drugs Ltd is currently trading near a key support level, with recent price action showing increased volume on upward movements, suggesting potential bullish momentum. If the stock breaks above the resistance level at $15, it could see an upside of approximately 20%. Conversely, if it falls below the support level at $12, a downside of around 15% is possible.
Upside Probability: 20% | Downside Probability: 15%
Probability estimates are technical-context statements, not investment advice.
More Options
J
JG Chemicals Ltd
JG Chemicals Ltd shows potential in a growing sector, but faces challenges in profitability and execution risks.
View details
T
Talbros Automotive Components Ltd
Talbros Automotive Components Ltd shows potential in a transitioning sector, but faces challenges in profitability and valuation metrics.
View details
P
Panama Petrochem Ltd
Panama Petrochem Ltd shows potential but faces significant challenges that could impact future performance.
View details
M
Master Trust Ltd
Master Trust Ltd shows potential but faces challenges in profitability and market sentiment. Caution is advised.
View details
T
TCC Concept Ltd
TCC Concept Ltd presents several risks with inconsistent growth and profitability metrics, alongside high valuation concerns. Caution is advised for potential investors.
View details
M
Motisons Jewellers Ltd
Motisons Jewellers Ltd shows potential in a growing sector, but faces challenges in profitability and market competition.
View details
U
Unitech Ltd
Unitech Ltd presents significant risks with limited growth prospects and financial instability.
View details
A
Aurum Proptech Ltd
Aurum Proptech Ltd shows potential in a growing sector, but faces challenges in execution and profitability. Caution is advised.
View details
F
Frontier Springs Ltd
Frontier Springs Ltd shows potential in a growing sector but faces challenges in profitability and valuation. Caution is advised for investors.
View details
A
All Time Plastics Ltd
All Time Plastics Ltd shows potential but faces several challenges that may hinder growth and profitability.
View details
W
Wheels India Ltd
Wheels India Ltd shows potential for growth but faces challenges in profitability and valuation metrics. Caution is advised for new investments.
View details
I
IFGL Refractories Ltd
IFGL Refractories Ltd shows a decent investment potential with strong fundamentals, but investors should be cautious of valuation and governance issues.
View details
D
Dredging Corporation of India Ltd
Dredging Corporation of India Ltd presents several challenges, including inconsistent growth and profitability metrics, alongside governance concerns. The sector's future is uncertain due to competitive pressures and regulatory hurdles.
View details
P
Pnb Gilts Ltd
Pnb Gilts Ltd shows moderate potential but faces challenges in growth and profitability metrics.
View details
Q
Quick Heal Technologies Ltd
Quick Heal Technologies Ltd shows potential in a growing sector, but faces significant risks and inconsistent performance metrics.
View details
H
Hester Biosciences Ltd
Hester Biosciences Ltd shows potential for growth in a favorable sector, but faces challenges in profitability consistency and valuation metrics.
View details
Business Overview
Beta Drugs Ltd is a leading pharmaceutical company in India, dedicated to developing innovative and affordable medications. With a focus on quality and patient care, we cater to a diverse range of therapeutic areas, ensuring accessibility for all. Our commitment to research and development drives us to create effective solutions that meet the healthcare needs of the nation. Beta Drugs Ltd is trusted by healthcare professionals and patients alike, making a significant impact on the Indian healthcare landscape.
- Established leader in the Indian pharmaceutical industry
- Focus on affordability and accessibility of medications
- Diverse therapeutic areas to cater to various health needs
- Strong commitment to research and development
- Trusted by healthcare professionals and patients
- Contributing to the improvement of public health in India
Investment Thesis
Beta Drugs Ltd presents a compelling investment opportunity due to its strong promoter credibility, significant growth potential in digital services, and attractive valuation compared to its peers. The company's robust fundamentals and strategic positioning in the market make it a promising choice for investors seeking long-term gains.
- Strong promoter group with a proven track record enhances investor confidence.
- Growing digital services segment poised for substantial revenue growth.
- Attractive valuation metrics compared to industry peers indicate potential upside.
- Commitment to innovation and quality positions the company for future success.
- Strategic partnerships and expansion plans further bolster growth prospects.
Opportunity vs Risk
Opportunities
- Growing demand for healthcare products
- Expansion into new markets
- Strong R&D pipeline
- Strategic partnerships with hospitals
- Increasing online sales channels
Risks ⚠️
- Regulatory changes affecting approvals
- High competition in pharmaceuticals
- Dependence on key patents
- Supply chain disruptions
- Market volatility impacting sales
Peer Perspective
Beta Drugs Ltd trades at a 15% discount to peers like Sun Pharma and Dr. Reddy's, reflecting concerns over margin stability; a consistent improvement in operational efficiency could trigger a rerating.
Future Outlook
Beta Drugs Ltd has strong growth potential driven by innovative product pipelines, but successful execution and effective cost control will be crucial to capitalize on market opportunities and sustain profitability in the coming years.
AI FAQs for Retail Users
- Q: What does Beta Drugs Ltd do?A: Beta Drugs Ltd is involved in the development and manufacturing of pharmaceutical products.
- Q: Is Beta Drugs Ltd a profitable company?A: Profitability can vary; check the latest financial reports for current performance.
- Q: What are the risks of investing in Beta Drugs Ltd?A: Like any stock, risks include market volatility, regulatory changes, and company-specific challenges.
- Q: How can I buy shares of Beta Drugs Ltd?A: You can purchase shares through a registered stockbroker or an online trading platform.
- Q: Where can I find more information about Beta Drugs Ltd?A: Visit their official website or check financial news platforms for updates.
📊 Stock Investment Checklist (100 Points)
Beta Drugs Ltd • Updated: 2025-09-17 06:25:37
-
8BusinessHighThe pharmaceutical sector is growing, but competition is intense.
-
10GrowthHighRevenue growth has been inconsistent over the past few years.
-
10ProfitabilityHighROE and ROCE are decent, but OCF is volatile.
-
9ValuationHighValuation metrics are slightly above industry average.
-
6BalanceGoodModerate debt levels, but liquidity is a concern.
-
7GovernanceHighPromoter holding is strong, but some pledging exists.
-
5DriversGoodLimited growth drivers identified; execution risks are present.
-
1TechnicalsLowMarket sentiment is weak with low liquidity.
Final Score & Verdict
Score 48 / 100
• Decent
Beta Drugs Ltd shows potential but faces challenges in growth consistency and market sentiment.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 70/100
- Growth Potential: 65/100
- Profitability: 60/100
- Governance: 75/100
- Market Confidence: 68/100